Global Cytomegalovirus Retinitis Market Report 2014 - Forecasts to 2018
M2 - 1 hr 1 min ago
Research and Markets (http://www.researchandmarkets.com/research/5rhbrc/global) has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. The Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis. An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug. According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis. Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - Hospira - Shire Other Prominent Vendors - Auritec Pharmaceuticals - Chimerix Pharmaceuticals - Isis Pharmaceuticals - pSivida - Sanofi For more information visit http://www.researchandmarkets.com/research/5rhbrc/global
Most active Nasdaq-traded stocks
AP - Wed Aug 27, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Wed Aug 27, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
After Yesterday's Rally of 1.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 27, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.07% Rise
Comtex SmarTrend(R) - Wed Aug 27, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.77. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $108.72 on volume of 16.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Gilead Sciences (GILD) Approaches New Upside Target of $110.54
Comtex SmarTrend(R) - Wed Aug 27, 11:42AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $106.59 and have already reached the first level of resistance at $108.40. Investors may be interested in a cross of the next upside pivot targets of $110.54 and $114.49.
Bristol-Myers Hepatitis C Therapy Approved in EU
at Investor's Business Daily - Wed Aug 27, 11:03AM CDT
Bristol-Myers Squibb (BMY) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza with...
Goldman Sachs' 50 Stocks That Matter Most to Hedge Funds
at The Street - Wed Aug 27, 9:58AM CDT
This list of 50 stocks from Goldman Sachs Spreadsheet are those that appear most frequently among the top holdings of hedge funds. The portfolio beat the S&P 500 YTD gain.
Is It Time to Buy AbbVie Stock?
Keith Speights, The Motley Fool - Motley Fool - Wed Aug 27, 9:45AM CDT
One month after two big announcements, the dust has settled somewhat for AbbVie . Those major announcements, of course, were a blow-out second quarter and the acquisition of Shire plc . In the first few days after the news hit the street,...
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
Kite Pharma (KITE) Shows Strength: Stock Rises 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:39AM CDT
Kite Pharma, Inc. (KITE) was a big mover last session, as its shares rose almost 18% on the day.
China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
3 Reasons Pfizer Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Wed Aug 27, 8:22AM CDT
Pfizer may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs. Over the past 16 years Pfizer's stock hasn't budged on a nominal basis. That doesn't mean Pfizer's management...
Roche, InterMune a Strategic Play in Midst of Inversions
at The Street - Wed Aug 27, 8:19AM CDT
As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.
Isis Pharmaceuticals, Inc. (ISIS) Surges: Stock Moves 10.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:11AM CDT
Isis Pharmaceuticals, Inc. (ISIS) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
PR Newswire - Wed Aug 27, 8:10AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Express Scripts Holding Company (NASDAQ: ESRX) and C.R. Bard, Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5998-100free.
Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:51AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose a little over 9% on the day.
Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.
Gilead, Jazz Among 4 Top Big Cap Medicals To Watch
at Investor's Business Daily - Wed Aug 27, 7:02AM CDT
Today's Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it...